Posted by Michael Wonder on 10 May 2017
Novartis heart failure treatment Entresto (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan
9 May 2017 - Entresto has been shown to reduce the risk of cardiovascular death and hospitalization in heart failure with reduced ejection fraction.
Novartis Pharmaceuticals Canada is pleased to announce that the heart failure treatment Entresto (sacubitril/valsartan) is now reimbursed by the public provincial drug plan in Ontario.
Entresto is also available through the public drug plans in Quebec, Saskatchewan and the Yukon. Novartis continues to work with other provinces to ensure eligible heart failure patients across Canada have equal access to Entresto™ as soon as possible.
"The reimbursement of Entresto through the Ontario Public Drug Program is an important milestone for people in Ontario with heart failure. We are pleased that the Ontario government is making this new treatment option available for those who will benefit," said Janice Murray, President, Novartis Pharmaceuticals Canada Inc. "Novartis is continuing to work collaboratively with drug programs in the remaining provinces to enable reimbursement of this important treatment across Canada."
